Retractable Technologies, Inc. — Q3 2022 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2022. The company designs, manufactures, and markets safety syringes and other medical products. Results are unaudited.
Financial performance
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Net sales | $23.1 million | $36.4 million | $82.1 million | $128.9 million |
| Gross profit / margin | $4.7 million / 20.5% | $13.4 million / 36.8% | $24.0 million / 29.2% | $61.0 million / 47.3% |
| Operating income (loss) | $(0.7) million | $8.0 million | $7.0 million | $44.1 million |
| Net income | $5.4 million | $6.5 million | $9.4 million | $35.1 million |
| Operating cash flow | Not separately provided | Not separately provided | $6.6 million | $18.1 million |
- Q3 net income included a $5.8 million income tax benefit despite a $0.4 million pretax loss. The company recorded an approximately $7 million state income tax benefit following a tax-apportionment review. Nine-month tax benefit was $1.5 million.
- Cash and cash equivalents were $13.4 million at September 30, down from $29.2 million at December 31, 2021. Total assets were $200.6 million; stockholders’ equity was $109.0 million.
- Current assets were $91.8 million and current liabilities $15.0 million (working capital of $76.8 million). Current assets included $26.3 million of equity securities and $13.0 million of income taxes receivable.
- Long-term debt, including current maturities, was approximately $1.9 million. Separately, $75.0 million of other long-term liabilities related primarily to deferred TIA funding; this is not reported as debt.
- Investing cash outflow was $28.2 million, including $13.9 million for property and equipment and net purchases of equity securities. Financing cash inflow was $5.8 million, primarily reflecting $10.1 million of TIA proceeds, partly offset by share repurchases and other payments.
Changes and operating drivers
- Sales fell 36.6% in Q3 and 36.3% for the first nine months year over year. The principal factor was the absence of U.S. government syringe orders in Q2 and Q3; government sales in the first nine months were $15.7 million, all reported in Q1.
- International revenue increased sharply from the prior-year comparison, but international sales generally generate lower revenue per unit than U.S. sales and may reduce overall margins. Management cited uncertainty about timing of future international orders.
- Q3 overall unit sales declined 11.3%; nine-month unit sales declined 21.4%. Lower production volumes and higher per-unit costs contributed to weaker profitability. Operating expenses were broadly unchanged.
- Freight costs remained elevated and weighed on manufacturing costs. Shanghai port closures delayed shipments into Q3. The company said costs may not be recoverable through price increases.
- The company reduced its workforce by approximately 16% in June 2022 after completing much of its facility expansion and U.S. government order work. It had approximately 204 employees at quarter-end.
- The company repurchased approximately $2.8 million of common stock in the first half of 2022. Its repurchase plan ended April 14, 2022, after 1,087,145 shares had been purchased for approximately $8.1 million in total.
Outlook, risks, and contingencies
- No quantified revenue or earnings guidance is provided. Management said it expects adequate resources to meet short-term needs for at least 12 months and currently foreseeable long-term needs, drawing on operations, cash reserves, and investments that could be liquidated. It does not use a line of credit.
- Future U.S. government product orders are uncertain. Management cautioned that pandemic-related delivery orders and the TIA may not indicate future operations; expanded manufacturing capacity could be underused if demand is insufficient.
- The TIA provides up to approximately $81 million for domestic production expansion. The company reported approximately $75.5 million received for fixed-asset down payments and negotiated equipment contracts of approximately $66.2 million. The administrative-office expansion was expected to be completed in late November 2022, with approximately $650,000 remaining to be spent as of November 4.
- Supply-chain and sourcing exposure is significant: Chinese manufacturers supplied approximately 94% of products in Q3 and roughly 92% during the first nine months. Disruption could require alternate suppliers or expanded domestic production.
- Customer concentration is high: significant customers represented 67.4% of Q3 sales and 73.0% of nine-month sales. Equity securities represented 28.7% of current assets and were subject to market-value changes.
- A legal-malpractice and negligence action against former counsel remains pending. The court dismissed the company’s fiduciary-duty claim, while another defense motion was denied. A trial set for January 2023 was subject to an agreed continuance motion proposing April 3, 2023. The filing does not provide a clear estimate of any potential recovery or loss.
- The filing reports no material changes to the risk factors in the latest annual report. Management said disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether and when additional U.S. government orders or international orders materialize, and the extent to which demand can utilize expanded capacity.
- Whether freight, supplier, tariff, and production costs continue to pressure gross margins, and whether product pricing can offset those costs.
- The composition, liquidity, and market-value risk of the $26.3 million investment portfolio, and the timing of tax receivable recovery.
- The progress and remaining commitments of the TIA-funded expansion, including the distinction between deferred TIA liabilities and borrowing.
- Developments in the legal case, dividends payable to former preferred shareholders, and any related cash requirements.